TherapeuticsMD, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M |
| Cost of revenue | — | — | — | $1.4M | $1.4M |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M |
| Selling, general & administrative | — | $4.7M | $8.9M | — | — |
| Research and development | — | — | — | — | $7.1M |
| Operating expenses | $7.4M | $7.9M | $9.8M | $67.4M | $80.7M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M |
| Interest expense | — | — | $300,000 | $200,000 | $32.9M |
| Pretax income | -$653,000 | -$2.3M | -$7.7M | $1.1M | -$79.3M |
| Income tax expense | — | -$31,000 | -$43,000 | — | — |
| Net income | -$569,000 | -$2.2M | -$10.3M | $112.0M | -$172.4M |
| Balance Sheet | |||||
| Cash and equivalents | — | $5.1M | $4.3M | — | — |
| Current assets | $14.4M | $12.3M | $11.8M | $55.4M | $119.5M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M |
| Current liabilities | $4.8M | $5.2M | $6.9M | $46.8M | $252.9M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M |
| Stockholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M |
| Cash Flow Statement | |||||
| Cash from operations | $2.5M | $1.2M | -$23.1M | $9.4M | -$142.7M |
| Depreciation and amortization | $384,000 | $509,000 | $100,000 | $600,000 | $400,000 |
| Stock-based compensation | $75,000 | $264,000 | $1.3M | $11.6M | $18.1M |
| Capital expenditure | — | — | — | — | $34,000 |
| Free cash flow | — | — | — | — | -$142.7M |
| Impairments | — | $1.3M | — | — | — |
Shares outstanding 11.6M · Free float 98.3%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.